Shanxi C&Y Pharmaceutical Group Co.,ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is a pharmaceutical listed group enterprise that integrates research and development, production, and marketing. The predecessor of the company, Shanxi Qianyuan Pharmaceutical Co., Ltd., was established on March 23, 2005. It provides products and services in 34 provincial-level administrative regions across the country and gradually extends its business to international markets and precision medical fields. The company changed its name to Shanxi Qianyuan Pharmaceutical Co., Ltd. in June 2010 and was successfully listed on the Shenzhen Stock Exchange Growth Enterprise Board on August 19, 2011. In September 2014, the company was renamed Shanxi Qianyuan Pharmaceutical Group Co., Ltd., with the securities abbreviation "Qianyuan Pharmaceutical" (stock code: 300254). In the process of development, Qianyuan Pharmaceutical has relied on its keen market sense and strategic vision, continuously using methods such as extensive mergers and investments to help enterprises quickly seize market opportunities, optimize product structure, and achieve leapfrog development. As of now, the group has 10 wholly-owned and controlled subsidiaries, including Hangzhou Baoling Pharmaceutical, Zhejiang Hailisheng Pharmaceutical, Jiangsu Jiayi Pharmaceutical, Hangzhou Enshi Gene, Sichuan Qianyuan Traditional Chinese Medicine, Wuxi United Likang Inspection, and Tibet Qianyuan. The group headquarters and marketing department are located in Shanghai. Qianyuan Pharmaceutical has a modern production base, distribution center and a high-level R&D team. It has a strong industrial foundation in many fields, such as chemical synthetic drugs, biological drugs, natural drugs, API intermediates, traditional Chinese patent medicines and simple preparations, Chinese herbal pieces, nutritional health products, pharmaceutical circulation, and is committed to building a large pharmaceutical and health industry group in the whole industry chain of the pharmaceutical industry. In order to adapt to the constantly changing situation in the pharmaceutical industry and focus on long-term development in the future, Qianyuan Pharmaceutical has redefined its development strategy in 2020, with high-end pharmaceuticals as the core and precision medicine and health food as the two wings. Relying on the group's advanced pharmaceutical research institute and mature marketing system, Qianyuan Pharmaceutical continuously enhances its core competitiveness and market position. Qianyuan People will continue to uphold the corporate spirit of "Challenge&Young" and the corporate values of "professionalism, integrity, progress, and sharing", with the goal of achieving "Top 100 Pharmaceutical Enterprises, a Hundred Billion Market Value, and a Healthy, Stable, and Sustainable Development Centennial Enterprise", fulfilling their mission and fulfilling their youthful aspirations. Make progress with the world and make health simpler. |
| Headquarter | Datong City |
| Establish Date | 3/23/2005 |
| Listed Code | 300254.SZ |
| Listed Date | 8/19/2011 |
| Chairman | Huang Lequn. |
| CEO | Zhao Qun. |
| Website | www.cy-pharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
